Target intelligence / Profile preview

Group Y capsular polysaccharide of Neisseria meningitidis

Molecular classification: Polysaccharide antigen, Bacterial capsule component, Other (not a protein, enzyme, receptor or transporter; it is a complex carbohydrate)

Overview

The Group Y capsular polysaccharide of Neisseria meningitidis is a linear, high-molecular-weight carbohydrate polymer that composes the capsule surrounding Neisseria meningitidis bacteria of serogroup Y. It consists of alternating units of N-acetylneuraminic acid (sialic acid) linked to glucose via specific glycosidic bonds, forming a helical structure with distinct hydrophilic and hydrophobic surfaces. This capsule is the principal virulence determinant for the bacterium, allowing it to evade the host immune system, resist complement-mediated lysis, and cause invasive diseases such as meningitis and septicemia. The group Y polysaccharide is a key antigen in quadrivalent meningococcal conjugate vaccines (MenACWY). Detection of antibodies to this polysaccharide is used as a biomarker for vaccine-induced immunity.

Other names: Group Y capsular polysaccharideSerogroup Y capsular polysaccharideNeisseria meningitidis serogroup Y capsuleNmY capsular polysaccharide

Mechanism of action

Conjugate vaccines induce protective antibodies that recognize the group Y capsular polysaccharide, promoting bacterial clearance via opsonization and complement-mediated lysis

Biological functions

Immune evasion (prevents opsonization and lysis by host complement system)Major virulence factor (required for systemic invasive disease)Basis for vaccine antigenicity (elicits protective immune responses)

Disease associations

Infection (major determinant of Neisseria meningitidis pathogenicity, responsible for invasive meningococcal disease)

Safety considerations

Polysaccharide antigens alone can have limited immunogenicity in infants and young children, requiring conjugation to a carrier protein for effective vaccinationRare risk of immune escape through capsule switching or downregulationHypersensitivity to vaccine components (general vaccine concern)

Interacting drugs

Meningococcal conjugate vaccines containing group Y polysaccharide (e.g., MenACWY vaccines)

Biomarkers

Anti-group Y capsular polysaccharide IgG (serological marker for immunity and vaccine response)

Beyond the preview

Go deeper on Group Y capsular polysaccharide of Neisseria meningitidis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Group Y capsular polysaccharide of Neisseria meningitidis.

Explore the full profile